COFCO Biotechnology Past Earnings Performance
Past criteria checks 0/6
COFCO Biotechnology's earnings have been declining at an average annual rate of -15.4%, while the Chemicals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 1.8% per year.
Key information
-15.4%
Earnings growth rate
-15.4%
EPS growth rate
| Chemicals Industry Growth | 12.1% |
| Revenue growth rate | 1.8% |
| Return on equity | -5.5% |
| Net Margin | -2.8% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How COFCO Biotechnology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 20,588 | -578 | 777 | 170 |
| 31 Dec 23 | 20,379 | -602 | 789 | 165 |
| 30 Sep 23 | 19,743 | -240 | 797 | 149 |
| 30 Jun 23 | 18,619 | -63 | 798 | 118 |
| 31 Mar 23 | 19,060 | 711 | 794 | 119 |
| 01 Jan 23 | 19,918 | 1,059 | 807 | 133 |
| 30 Sep 22 | 20,370 | 1,160 | 777 | 85 |
| 30 Jun 22 | 22,142 | 1,215 | 780 | 114 |
| 31 Mar 22 | 23,320 | 1,123 | 827 | 132 |
| 01 Jan 22 | 23,560 | 1,130 | 815 | 119 |
| 30 Sep 21 | 24,011 | 994 | 837 | 135 |
| 30 Jun 21 | 22,630 | 928 | 840 | 144 |
| 31 Mar 21 | 21,460 | 848 | 795 | 105 |
| 31 Dec 20 | 19,909 | 593 | 799 | 114 |
| 30 Sep 20 | 19,569 | 737 | 1,028 | 131 |
| 30 Jun 20 | 19,883 | 772 | 1,263 | 101 |
| 31 Mar 20 | 18,935 | 636 | 1,565 | 91 |
| 31 Dec 19 | 19,472 | 593 | 1,810 | 87 |
| 30 Sep 19 | 18,424 | 332 | 1,799 | 65 |
| 30 Jun 19 | 17,720 | 304 | 1,921 | 80 |
| 31 Mar 19 | 17,850 | 430 | 1,846 | 82 |
| 31 Dec 18 | 17,704 | 483 | 1,851 | 96 |
| 30 Sep 18 | 24,480 | 1,254 | 2,789 | 176 |
| 30 Jun 18 | 21,848 | 1,070 | 2,336 | 168 |
| 31 Mar 18 | 18,821 | 967 | 2,058 | 146 |
| 31 Dec 17 | 15,892 | 929 | 1,768 | 101 |
| 30 Sep 17 | 6,164 | 237 | 460 | 22 |
| 30 Jun 17 | 5,898 | 339 | 497 | 0 |
| 31 Mar 17 | 5,854 | 232 | 555 | 0 |
| 31 Dec 16 | 5,603 | 127 | 558 | 0 |
| 30 Sep 16 | 5,446 | -801 | 608 | 0 |
| 30 Jun 16 | 5,593 | -1,083 | 612 | 0 |
| 31 Mar 16 | 6,186 | -1,265 | 553 | 0 |
| 31 Dec 15 | 6,457 | -1,418 | 535 | 0 |
| 30 Sep 15 | 6,704 | -509 | 456 | 0 |
| 30 Jun 15 | 7,155 | -312 | 475 | 0 |
| 31 Mar 15 | 6,930 | -166 | 454 | 0 |
| 31 Dec 14 | 7,153 | 35 | 463 | 0 |
| 30 Sep 14 | 7,102 | 24 | 490 | 0 |
| 30 Jun 14 | 7,074 | 32 | 478 | 0 |
| 31 Mar 14 | 7,186 | 39 | 456 | 0 |
| 31 Dec 13 | 7,340 | 51 | 459 | 0 |
| 30 Sep 13 | 7,588 | 130 | 481 | 0 |
| 30 Jun 13 | 7,611 | 143 | 523 | 0 |
Quality Earnings: 000930 is currently unprofitable.
Growing Profit Margin: 000930 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 000930 is unprofitable, and losses have increased over the past 5 years at a rate of 15.4% per year.
Accelerating Growth: Unable to compare 000930's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 000930 is unprofitable, making it difficult to compare its past year earnings growth to the Chemicals industry (-19.7%).
Return on Equity
High ROE: 000930 has a negative Return on Equity (-5.5%), as it is currently unprofitable.